secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008507
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022
-------------------------------------------------------------------------

- Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.
- Cash, cash equivalents and investments $352.3M at March 31, 2022, including $107.6M net from public offering.
- VAX-24 Phase 1/2 study dosing in both phases; topline safety, tolerability, immunogenicity results expected by year-end 2022.
- Separate VAX-24 Phase 2 study in adults 65+ expected to start mid-2022; topline results expected H1 2023.
- Appointed Mikhail Eydelman as SVP, General Counsel & Corporate Secretary in April 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/0000950170-22-008507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/pcvx-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer